In the case of neuroblastoma, 131I-metaiodobenzylguanidine (131I-MIBG), a radiopharmaceutical targeting the norepinephrine transporter highly expressed in neuroblastoma cells, showed promise in a phase II trial. This evidence concerns the gene SLC6A2 and neuroblastoma.